BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32224882)

  • 1. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update.
    Kishore SA; Bajwa R; Madoff DC
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32224882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.
    Makary MS; Khandpur U; Cloyd JM; Mumtaz K; Dowell JD
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32679897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraarterial Therapies for the Management of Hepatocellular Carcinoma.
    Garg T; Shrigiriwar A; Habibollahi P; Cristescu M; Liddell RP; Chapiro J; Inglis P; Camacho JC; Nezami N
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy.
    Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V
    BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional and systemic therapy for hepatocellular carcinoma.
    Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
    J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
    Makary MS; Ramsell S; Miller E; Beal EW; Dowell JD
    World J Gastroenterol; 2021 Nov; 27(43):7462-7479. PubMed ID: 34887643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
    Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
    J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New concepts in embolotherapy of HCC.
    Pesapane F; Nezami N; Patella F; Geschwind JF
    Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.
    Vogl TJ; Gruber-Rouh T
    Dig Dis Sci; 2019 Apr; 64(4):959-967. PubMed ID: 30835030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments.
    Gnutzmann D; Kortes N; Sumkauskaite M; Schmitz A; Weiss KH; Radeleff B
    Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):69-80. PubMed ID: 29381102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial Therapies for Hepatocellular Carcinoma.
    Lanza E; Donadon M; Poretti D; Pedicini V; Tramarin M; Roncalli M; Rhee H; Park YN; Torzilli G
    Liver Cancer; 2016 Nov; 6(1):27-33. PubMed ID: 27995085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.
    Thornton LM; Cabrera R; Kapp M; Lazarowicz M; Vogel JD; Toskich BB
    Curr Probl Diagn Radiol; 2017; 46(6):402-409. PubMed ID: 28392205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
    Poon RT; Fan ST; Tsang FH; Wong J
    Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embolization of liver tumors: Past, present and future.
    Rammohan A; Sathyanesan J; Ramaswami S; Lakshmanan A; Senthil-Kumar P; Srinivasan UP; Ramasamy R; Ravichandran P
    World J Radiol; 2012 Sep; 4(9):405-12. PubMed ID: 23024842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
    Kolligs FT; Bilbao JI; Jakobs T; IƱarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
    Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Embolization Therapies for Hepatocellular Carcinoma.
    Kishore S; Friedman T; Madoff DC
    Curr Oncol Rep; 2017 Jun; 19(6):40. PubMed ID: 28421483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options.
    Pourbaghi M; Haghani L; Zhao K; Karimi A; Marinelli B; Erinjeri JP; Geschwind JH; Yarmohammadi H
    Curr Oncol; 2023 Jul; 30(7):6609-6622. PubMed ID: 37504345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.